OTC: RMTG

We support physicians, medical providers, and
affiliated clinics with the latest protocols, biologics, automated processing systems, diagnostic tools, and ongoing training. Our revenue
model is diversified and highly synergistic, encompassing professional training and certifications, recurring sales of Cellgenic products
(exosomes, mesenchymal stem cells, peptides, and combination therapies), premium clinical treatments, equipment and kits, digital subscriptions,
licensing, partnerships, and franchise arrangements. This fully integrated structure creates significant sustainable competitive advantages,
including elevated customer lifetime value, recurring revenue predictability, strong ecosystem lock-in, network effects, and proprietary
clinical data assets that inform product development and protocol refinement.

Forecast for Fiscal Year 2026

2026 represents a pivotal year of strategic execution
and platform maturation for RMTG and GSCG. Building on the foundational infrastructure established in prior periods, we expect to successfully
transition from a high-growth operator into a consolidated category leader in Regenerative Medicine. Through aggressive advancement of
our vertically integrated model, we anticipate substantial progress across education, manufacturing, clinical delivery, digital enablement,
and global market penetration. We anticipate that these initiatives will drive meaningful revenue acceleration, margin expansion, improved
operational efficiencies, and strengthen competitive advantages, while reinforcing our role as the reference institution and preferred
ecosystem for physicians worldwide.

ISSCA – Global Educational Dominance and Physician Network
Expansion

ISSCA solidified its position as the leading global
authority in regenerative medicine education. We executed a full calendar of 15 international events spanning five continents, including
major conferences, hands-on certifications, specialty-focused programs, and regional symposiums. This continuous market presence enabled
rapid penetration of emerging markets and the cultivation of a high-value, high-retention physician network. We expanded our educational
offerings into a multi-layered ecosystem, launching scalable online certifications, advanced specialty programs in orthopedics, aesthetics,
and longevity. In 2026 we expect to launch a new Diploma in Cell Therapy & Tissue Engineering, postgraduate-level curricula, and fellowship-style
training. ISSCA is evolving from a training organization into a standard-setting academic authority, creating a powerful flywheel: physicians
enter through education, adopt our protocols, integrate Cellgenic products and equipment, and remain engaged through continuous updates
and support. This strategy deepens physician dependency, standardizes clinical practices globally, and positions ISSCA as the gateway
to the broader regenerative medicine industry.

ISSCA Global Summit – Flagship Industry Event

The 2025 ISSCA Global Summit in Cancún,
attended by more than 470 doctors, professors, and medical professionals, served as the industry’s premier convergence point, featuring
high-level scientific and clinical content, a distinguished international speaker lineup, and integrated tracks on exosomes, peptides,
stem cells, longevity, biohacking, and AI in medicine. Far beyond a conference, the Summit functioned as a strategic asset that amplified
brand authority, drove high-conversion enrollment in certifications and product adoption, accelerated key opinion leader relationships,
and generated substantial content for year-round marketing. It reinforced ISSCA’s role in defining industry trends and clinical
standards while acting as a force multiplier for downstream revenue across education, products, and partnerships.

1

Cellgenic – Manufacturing Excellence and Product Portfolio
Expansion

Cellgenic advanced significantly with a fully
operational, scalable manufacturing infrastructure supporting advanced exosome production, mesenchymal stem cell (MSC) manufacturing,
peptide development, and quality-controlled biologics distribution. We broadened our portfolio to include next-generation exosome formulations,
peptide products, and combination therapy solutions (MSC + exosomes + peptides), along with ready-to-use clinical kits and systems. Cellgenic
manufactures and sells regenerative medicine products that are supplied to physicians and clinics participating in ISSCA programs. This
vertical integration introduced high-margin, recurring revenue streams through consumables, reduced reliance on third-party suppliers,
and created strong brand loyalty and switching costs for physicians. Manufacturing consistency, controlled quality environments, and standardized
protocols differentiated us in a market challenged by variable-quality alternatives, enabling premium positioning and margin expansion.
Cellgenic’s growth was directly amplified by ISSCA’s international footprint, following a repeatable model of market entry
through education, network building, product introduction, and distribution scaling.

Clinical Network – Premium Patient Experience and Scalable
Model

Our Cellular Institute and affiliated clinics
evolved into five-star regenerative medicine centers, emphasizing exceptional patient experience, expanded service lines (including biohacking,
anti-aging, hormone therapy, aesthetic medicine, and advanced cellular therapies), and integration of AI-assisted diagnostics and standardized
protocols. We made substantial progress toward a replicable franchise model, including standardization of design, equipment, treatment
protocols, staff training, and patient frameworks. Clinics served as direct monetization channels for high-ticket procedures while functioning
as validation platforms that generated real-world clinical data for protocol refinement, product improvement, and R&D. This feedback
loop continuously strengthened the entire ecosystem. Preparations for franchise and joint-venture expansion positioned the clinical division
as a scalable global network of centers of excellence, training hubs, and distribution points.

Cellular Institute and Stem Cell Center – Premium Clinical
Delivery and Patient Acquisition Platforms

The Cellular Institute serves as the Company’s
flagship clinical and research facility in Cancún, Mexico, functioning as the central hub for patient care, physician training,
product integration, and operational excellence. During 2025, we significantly expanded the Institute’s capabilities, transforming
it from a specialized regenerative medicine clinic into a comprehensive, multi-disciplinary treatment center. The facility now offers
an expanded portfolio of advanced therapeutic services, including plasmapheresis and blood-based therapies, regenerative medicine applications,
and integrative longevity-focused treatments. We invested in state-of-the-art recovery and performance optimization infrastructure, such
as hyperbaric oxygen therapy systems, electromagnetic field (PEMF) therapy equipment, and red/near-infrared light therapy. Clinical capabilities
were further strengthened with the addition of a fully equipped operating room and dedicated procedure suites for minimally invasive interventions.

On-site infrastructure now includes a dedicated
biologics processing laboratory, clean room environment, and distribution logistics center, enabling tight vertical integration of clinical
operations, product validation, and supply chain activities. The incorporation of artificial intelligence-supported decision tools, wearable
patient monitoring, and advanced data tracking systems has enhanced treatment personalization, outcomes analysis, and protocol optimization.
These developments position the Cellular Institute as a true center of excellence that supports high-quality clinical service delivery,
physician training through ISSCA, and the evaluation of emerging technologies.

Complementing the Institute, the Stem Cell Center
operates as our primary patient-facing clinical brand and service platform. It functions as the key interface for patient education, lead
generation, and treatment coordination across international markets. Through targeted digital channels and educational content, the Stem
Cell Center drives awareness and acquisition for stem cell-based therapies, exosome and biologic-based treatments, regenerative protocols
for chronic & degenerative conditions, and anti-aging/longevity interventions.

The platform seamlessly refers patients to the
Cellular Institute and our affiliated network while promoting utilization of the Company’s proprietary Cellgenic product portfolio.
By standardizing messaging, protocols, and the patient experience, the Stem Cell Center reinforces brand consistency and facilitates medical
tourism support, inquiry qualification, and coordinated treatment planning. Management believes that the continued enhancement of both
the Cellular Institute and the Stem Cell Center will meaningfully increase patient flow, improve conversion rates, strengthen global brand
recognition, and contribute to scalable, long-term revenue growth within our vertically integrated ecosystem.

2

Argentina – Regulatory Stronghold and Market Control

In 2026, Argentina emerged as a key strategic
market for RMTG by aligning our operations with the country’s established regulatory framework for advanced biologics and cell therapy
manufacturing. This alignment enabled compliant, controlled production and nationwide commercialization of Cellgenic products, allowing
us to establish exclusive distribution structures, standardize clinical protocols, and build a fully integrated national ecosystem combining
ISSCA education, product supply, and clinical services. The approach reduces regulatory risk, enhances credibility with physicians and
institutions, supports stronger pricing discipline, and accelerates physician network growth and product adoption. Argentina now serves
as both a concentrated revenue platform and a replicable blueprint for efficient expansion across Latin America.

Global Market Expansion

We executed a structured, repeatable “land
and expand” strategy focused on high-growth regions including Latin America (Argentina, Brazil, Mexico), the Middle East (UAE, Saudi
Arabia), Southeast Asia (Indonesia), South Asia (Pakistan), and Europe (Portugal, Spain, Italy). Leading with ISSCA education, followed
by Cellgenic product distribution and clinical partnerships, enabled capital-efficient entry, rapid network development, and accelerated
revenue generation. This approach produced powerful network effects, brand globalization, and risk diversification across multiple geographies.

AI and Digital Ecosystem Integration

We believe that a major differentiator in 2026
will be the successful launch and integration of the ISSCA AI Platform and ISSCA App. ISSCA AI delivers clinical decision support, protocol
recommendations, patient management, and workflow optimization, while the ISSCA App serves as the digital backbone for global physician
networking, education access, and community engagement. These tools create a scalable digital layer across education, clinics, products,
and data, introducing high-margin subscription revenue, network effects through data aggregation, and enhanced physician retention. The
digital infrastructure transitions the company toward a technology-enabled platform model with SaaS-like characteristics, improving valuation
potential and operational efficiency.

Revenue Model Synergies and Ecosystem Economics

Our multi-layered revenue model—training
and certifications, Cellgenic product sales, clinical treatments, equipment, licensing, partnerships, and digital subscriptions—operated
as a self-reinforcing engine. Each physician has a lifecycle stage (acquisition through education, activation via protocols, monetization
through products, expansion via advanced training, integration through clinics, and retention via digital platforms) that compounds in
value. This produced predictable recurring revenue, elevated customer lifetime value, operational efficiencies, and ecosystem lock-in.
The result was a shift from linear, transaction-based economics to compounding, platform-driven growth with higher margins and greater
predictability.

2026 Strategic Outlook

Building on the 2025 foundation of platform maturity
and global scale, our priorities for 2026 center on further ecosystem optimization, accelerated clinical network franchising, deeper AI-driven
personalization and data monetization, continued product innovation (including advanced combination therapies and delivery systems), and
targeted expansion into additional regulated markets such as North America. We will maintain disciplined capital allocation toward manufacturing
capacity enhancements, R&D pipeline advancement, and strategic partnerships that reinforce our category leadership. Key performance
indicators will focus on revenue growth, margin improvement, physician retention and lifetime value, clinical outcome metrics, digital
platform adoption, and facility utilization. With our vertically integrated model, recurring revenue base, proprietary data assets, and
global network effects firmly established, we are positioned to deliver sustained, high-quality growth while advancing regenerative medicine
standards worldwide.

3